Login to Your Account

Clinic Roundup

Thursday, December 6, 2012

• Peregrine Pharmaceuticals Inc., of Tustin, Calif., said it reached an agreement with the FDA on the design of a single registration trial testing Cotara in patients with recurrent glioblastoma multiforme.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription